Which treatment for high-risk patients with DLBCL?

Affiliations

Comment

Bertrand Coiffier. Lancet Oncol. 2012 Dec.

. 2012 Dec;13(12):1180-2.

doi: 10.1016/S1470-2045(12)70507-7. Epub 2012 Nov 16.

¹ Hospices Civils de Lyon: Centre Hospitalier Lyon-Sud, chemin du grand Revoyet, 69310 Pierre-Bénite, France. bertrand.coiffier@univ-lyon1.fr

No abstract available

Comment on

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).
Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B; German High-Grade Lymphoma Study Group (DSHNHL). Schmitz N, et al. Lancet Oncol. 2012 Dec;13(12):1250-9. doi: 10.1016/S1470-2045(12)70481-3. Epub 2012 Nov 16. Lancet Oncol. 2012. PMID: 23168367 Clinical Trial.